GLP-1 Receptor Therapy Explained for Cardiometabolic Impact

Uncover the effects of GLP-1 receptor therapy on cardiometabolic health and its significance in treatment strategies.

Abstract

Welcome to our educational post. I’m Dr. Alex Jimenez, and today, I will walk you through the modern, evidence-based shift from a glucose-only focus in diabetes to a comprehensive cardiometabolic model that reduces cardiovascular, renal, and mortality risks. We will explore a common clinical challenge called “over-basalization” of insulin and discuss why simply increasing basal insulin doses isn’t always the answer. Drawing on the latest research, we’ll journey through the groundbreaking findings from major cardiovascular outcome trials (CVOTs), what they revealed, and how those findings have changed guidelines across cardiology, endocrinology, and nephrology. I’ll detail the mechanisms and clinical benefits of SGLT2 inhibitors and GLP-1 receptor agonists in reducing major adverse cardiovascular events (MACE), heart failure hospitalizations, and progression of chronic kidney disease (CKD). Finally, I will describe how our multidisciplinary team at Injury Medical Clinic PA in El Paso integrates internal medicine oversight with my care as a chiropractor and functional medicine clinician to deliver cohesive, personalized protocols for metabolic, cardiovascular, and injury-related conditions.

Our Integrated Approach to Patient Care in El Paso

Here at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we pride ourselves on a unique, multidisciplinary approach to healthcare. I’m Dr. Alex Jimenez, and I lead a team dedicated to providing comprehensive care that goes beyond just treating symptoms. Our practice is built on a foundation of integrative medicine, where we combine the best of different disciplines to achieve optimal patient outcomes.

A key part of our collaborative model is our partnership with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist with over 40 years of invaluable experience (NPI #1164426749, Texas MD License #J2933). She serves as our Medical Director and Collaborative Physician, providing essential medical oversight and guidance. This structure, common in advanced injury and integrative care clinics, allows us to seamlessly merge my expertise in chiropractic care, functional medicine, and rehabilitation with her deep knowledge of internal medicine.

Together, we offer a spectrum of services, including:

• Medical Management: Overseen by Dr. Cardenas, ensuring that all treatments, including prescription medications for conditions such as diabetes and hypertension, are safe, effective, and aligned with evidence-based pharmacotherapy.
• Chiropractic Adjustments: To restore spinal alignment, improve nervous system function, and alleviate musculoskeletal pain.
• Functional Medicine: To identify and address the root causes of chronic disease through nutrition, lifestyle changes, and targeted supplementation.
• Rehabilitation and Personal Injury Care: To help patients recover from injuries, regain function, and return to their daily activities.

This integrated model allows us to look at the whole person. When we manage a patient with Type 2 diabetes, we don’t just focus on blood sugar numbers. We address the underlying inflammation, metabolic dysfunction, and musculoskeletal issues that often accompany the condition. Now, let’s explore a critical aspect of modern diabetes management.

Why Diabetes Care Now Starts With Cardiovascular and Renal Risk Reduction

As a clinician working at the intersection of chiropractic, functional medicine, and personal injury care, I’ve witnessed the cost of focusing solely on glucose. The data are unequivocal: people with diabetes face a disproportionately high burden of atherosclerotic cardiovascular disease (ASCVD), stroke, peripheral arterial disease, heart failure, and progressive kidney disease. More than 70% of individuals older than 65 with diabetes will ultimately die from heart disease or stroke, even when glucose is controlled.

This is why our care model at Injury Medical Clinic PA adopted a risk-reduction-first approach. We target:

• Blood pressure control
• Lipid optimization
• Glycemic control
• Weight management
• Physical activity
• Smoking cessation
• Sleep quality and stress modulation

The turning point came when leading organizations aligned on a shared paradigm. For the first time, the American College of Cardiology (ACC), American Heart Association (AHA), American Diabetes Association (ADA), and KDIGO (Kidney Disease: Improving Global Outcomes) converged on the same message: prioritize agents with proven cardiovascular and renal benefit—specifically, SGLT2 inhibitors and GLP-1 receptor agonists—based on the patient’s risk profile (ADA, 2023).

How FDA Cardiovascular Outcomes Trials Changed the Playbook

After safety signals from earlier agents (e.g., rosiglitazone) and other drug classes raised concerns about cardiovascular risk, the FDA in 2008–2009 required long-term cardiovascular outcomes trials (CVOTs) for antidiabetic medications to ensure they do not increase MACE—cardiovascular death, myocardial infarction, or stroke. What followed was a wave of rigorous, placebo-controlled, often event-driven trials. While the initial intent was safety, several agents—most notably in the SGLT2 inhibitor and GLP-1 receptor agonist classes—demonstrated not just neutrality but clear cardiovascular and renal benefit (FDA, 2008; Zinman et al., 2015; Marso et al., 2016).

This evidence shifted guidelines toward a “risk-pathway-first” strategy. For patients with established ASCVD, heart failure, or CKD—or those at high risk—therapies with outcome-proven benefits are now recommended irrespective of baseline A1c or background metformin use (ADA, 2023; ACC/AHA, 2019).

Understanding Over-Basalization: When More Insulin Isn’t Better

Let’s start by looking at a common scenario through a case study. Imagine a patient we’ll call Tony.

• Tony is a 62-year-old man who has lived with Type 2 diabetes for 11 years.
• His last A1c was 8.2%, which is significantly above the target goal for most individuals.
• He also has hypertension, hyperlipidemia, and proteinuria (protein in his urine), indicating early kidney stress.
• His current medications include:

• • Insulin Degludec (a basal insulin) at 65 units daily.
  • Metformin 1000 mg twice a day.
  • An SGLT-2 inhibitor
  • A statin for cholesterol.
  • An ARB for blood pressure.

Tony reports that his morning fasting glucose levels are between 110 and 150 mg/dL. However, his postprandial (after-meal) glucose levels, checked two hours after eating or at bedtime, are much higher, ranging from 160 to 200 mg/dL. His BMI is 32.5, placing him in the obese category.

Tony’s case is a classic example of a phenomenon we call over-basalization. This occurs when we continue to increase a patient’s basal insulin dose without achieving glycemic control, particularly in the presence of post-meal glucose spikes.

Defining Over-Basalization:

• Dose: The patient is taking more than 5 units of basal insulin per kilogram of body weight per day. Tony weighs about 100 kg (220 lbs), so his threshold would be around 50 units. He is on 65 units.
• Post-Meal Glucose: Levels are consistently above 180 mg/dL.
• A1c: The A1c remains above goal despite fasting glucose levels being near optimal.
• Bedtime-to-Morning Differential: The drop in blood sugar from bedtime to morning exceeds 50 mg/dL. Tony’s bedtime sugars are high (e.g., 200 mg/dL), and his morning sugars are lower (e.g., 110 mg/dL), showing a significant drop that suggests the basal insulin is working overnight but failing to control daytime sugars.

Research shows that beyond a certain point, typically around 0.5 units/kg/day, increasing basal insulin provides only a modest benefit on blood sugar while significantly increasing the risk of weight gain and hypoglycemia (low blood sugar). Pharmacokinetic studies on obese patients with type 2 diabetes confirm this ceiling effect (Heise et al., 2011). When a patient on 0.3 units/kg/day or more is still not at goal, we must think beyond just adding more basal insulin.

Intensifying Treatment: GLP-1 Agonists vs. Prandial Insulin

For a patient like Tony, who is already on a robust regimen of basal insulin, metformin, and an SGLT-2 inhibitor, what’s the next logical step?

1. Add Prandial (Mealtime) Insulin: This is a traditional approach. We could add a rapid-acting insulin shot before his largest meal to cover the post-meal glucose spike. However, this strategy has significant downsides. It often leads to weight gain and carries a much higher risk of hypoglycemia. For Tony, who is already struggling with his weight, adding a medication known to cause further weight gain is not ideal.
2. Add a GLP-1 Receptor Agonist: This is an increasingly preferred strategy, and for good reason. GLP-1 receptor agonists are a class of injectable (and now one oral) medications that work by mimicking the action of a natural hormone in our body called glucagon-like peptide-1.

The American Diabetes Association (ADA) guidelines strongly recommend considering a GLP-1 receptor agonist before initiating prandial insulin for most patients needing treatment intensification beyond basal insulin (American Diabetes Association, 2024).

Understanding the Incretin Effect and GLP-1 Agonists

For years, researchers were puzzled by a specific physiological phenomenon. They observed that when a person consumed glucose orally, their body produced a much stronger insulin response compared to when the same amount of glucose was administered intravenously. This led to a groundbreaking discovery: when food enters the gut, it triggers the release of special hormones called incretins.

These incretins, primarily Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP), travel through the bloodstream to the pancreas. There, they send a powerful signal to release insulin in a glucose-dependent manner. This means insulin is released only when blood sugar is high, which significantly reduces the risk of hypoglycemia compared with older diabetes medications.

We’ve found that in many individuals with type 2 diabetes, the incretin effect is blunted or, in some cases, completely absent. Their bodies produce insufficient amounts of native GLP-1. This defect helps explain the dual challenge many face: poor blood sugar control and difficulty with satiety, often leading to obesity. This is precisely where GLP-1 receptor agonists come into play. These medications are designed to mimic the action of our natural GLP-1, effectively restoring this crucial hormonal signaling pathway.

SGLT2 Inhibitors: Cardiovascular and Renal Protection Beyond Glucose

SGLT2 inhibitors reduce glucose reabsorption in the proximal tubule, promoting glucosuria and natriuresis. Their broad organ protection appears to stem from several interconnected mechanisms beyond glucose lowering alone.

Evidence highlights:

• EMPA-REG OUTCOME (empagliflozin): reduced MACE, cardiovascular death, and heart failure hospitalizations in patients with type 2 diabetes and ASCVD (Zinman et al., 2015).
• CANVAS Program (canagliflozin): reduced MACE and heart failure hospitalizations (Neal et al., 2017).
• DECLARE–TIMI 58 (dapagliflozin): reduced heart failure hospitalizations; neutral for three-point MACE overall but significant benefit in heart failure endpoints (Wiviott et al., 2019).

Heart failure trials (with and without diabetes):

• DAPA-HF (dapagliflozin): ~26% relative risk reduction for composite of CV death or heart failure hospitalization in HFrEF, irrespective of diabetes (McMurray et al., 2019).
• EMPEROR-Reduced and EMPEROR-Preserved (empagliflozin): reduced risk of CV death or heart failure hospitalization in both HFrEF and HFpEF populations (Packer et al., 2020; Anker et al., 2021).

Renal outcomes:

• DAPA-CKD: dapagliflozin reduced risk of sustained eGFR decline, end-stage kidney disease, or renal/CV death; the trial was stopped early for efficacy (Heerspink et al., 2020).
• EMPA-KIDNEY: empagliflozin reduced cardiorenal outcomes in CKD with and without diabetes (The EMPA-KIDNEY Collaborative Group, 2022).

GLP-1 Receptor Agonists: MACE Reduction and Vascular Protection

Landmark trials:

• LEADER (liraglutide): significant reduction in MACE and CV death (Marso et al., 2016).
• SUSTAIN-6 (semaglutide): reduced MACE; strong signals on stroke reduction (Marso et al., 2016).
• REWIND (dulaglutide): reduced MACE even in a lower-risk population with many participants without established ASCVD (Gerstein et al., 2019).
• PIONEER 6 (oral semaglutide): confirmed the cardiovascular safety of the first oral GLP-1 agonist, showing a trend toward MACE reduction.
• The FLOW trial for semaglutide was stopped early due to overwhelmingly positive results in reducing the risk of kidney disease progression (nephropathy).

More recently, Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, has shown even more dramatic effects on A1c and weight loss. While its dedicated CVOT (SURPASS-CVOT) is ongoing, initial data is extremely promising.

Mechanistic Deep Dive: Linking Organs and Outcomes

The power of these medications lies in their multifaceted mechanisms of action that influence multiple systems throughout the body simultaneously.

Why SGLT2s work: physiological underpinnings

• Hemodynamic renal protection: By restoring tubuloglomerular feedback, SGLT2s reduce intraglomerular pressure, limiting hyperfiltration and shear stress that drive glomerulosclerosis.
• Natriuresis and osmotic diuresis: Lower preload and afterload, reducing ventricular wall stress and improving heart failure symptoms and outcomes.
• Metabolic efficiency: Shift myocardial substrate utilization toward ketone bodies, which may be a more oxygen-efficient fuel for the failing heart, improving energetics.
• Anti-inflammatory and antifibrotic effects: Reduced oxidative stress and fibrosis signaling may stabilize vulnerable plaques and adverse myocardial remodeling.

Mechanisms: why GLP-1 RAs protect the heart and vessels

• Slowing Gastric Emptying: These drugs slow the rate at which food leaves the stomach, creating a prolonged feeling of satiety that supports weight loss.
• Boosting Insulin Secretion: They enhance the release of insulin precisely when it’s needed—after a meal when blood glucose levels rise.
• Suppressing Glucagon Secretion: They inhibit glucagon secretion, preventing unnecessary glucose production by the liver.
• Central Nervous System Effects: They act directly on the brain’s appetite centers, reinforcing satiety and reducing cravings.
• Anti-atherosclerotic biology: Reduce inflammation (e.g., CRP), improve endothelial function, and possibly stabilize plaques.

ADA’s Two-Track Algorithm: Tailoring Therapy to Risk

The ADA’s 2023 standards highlight two paths:

• Lower-risk or early diabetes: prioritize glucose-lowering tailored to A1c targets, side effects, cost, comorbidities, and patient preferences.
• High-risk (ASCVD, heart failure, CKD, or multiple risk factors): prioritize therapies with outcome benefits.

Key therapeutic positioning:

• For ischemic ASCVD: start a GLP-1 receptor agonist with proven CV benefit; consider adding an SGLT2 inhibitor if appropriate.
• For heart failure (especially HFrEF and now HFpEF): choose an SGLT2 inhibitor.
• For CKD with albuminuria or declining eGFR: choose an SGLT2 inhibitor; consider GLP-1 receptor agonists with renal signals where indicated.

Importantly, the guidelines support combining an SGLT2 inhibitor with a GLP-1 receptor agonist for additive protection in high-risk patients (ADA, 2023).

---

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

---

Integrative Chiropractic and Functional Medicine Within a Medical Oversight Framework

Our clinic’s multidisciplinary model reflects modern integrative and injury-care best practices. Dr. Cardenas confirms indications and contraindications, manages antihyperglycemics (SGLT2 inhibitors, GLP-1 RAs), and monitors renal function and hemodynamics. My role is to complement this with chiropractic care and functional medicine.

How we integrate care:

• Managing Systemic Inflammation: Metabolic syndrome is a state of chronic inflammation. While a GLP-1 agonist helps reduce this systemically, our chiropractic care addresses the biomechanical consequences. By performing spinal and extremity adjustments, we improve joint mobility and reduce nerve interference.
• Supporting Weight Loss and Mobility: The weight loss from GLP-1 agonists reduces stress on joints. We design personalized rehabilitation programs to help patients build strength, improve balance, and enhance mobility, allowing them to engage in crucial physical activity.
• Nutritional and Lifestyle Counseling: As a Certified Functional Medicine Practitioner, I emphasize that medication is one piece of the puzzle. We provide detailed nutritional guidance, prioritizing protein, high-fiber foods, and adequate hydration to complement the effects of these medications.

Why integrative chiropractic makes medical therapy work better:

• Autonomic rebalancing: Sympathetic overdrive elevates heart rate, blood pressure, and inflammatory tone. Chiropractic care, breathing training, and vagal-stimulating routines can improve heart rate variability and stress recovery, complementing the benefits of SGLT2 inhibitors and GLP-1 RAs.
• Kinetic chain optimization: By restoring joint mechanics and reducing pain, patients can sustain aerobic and resistance training that reduce visceral adiposity, improve insulin signaling, and lower blood pressure.
• Neuroimmune modulation: Persistent pain elevates inflammatory cytokines. Hands-on care reduces nociceptive drive and supports systemic anti-inflammatory states, reinforcing vascular benefits.
• Sleep restoration: Pain control can improve sleep architecture; better sleep improves glycemic control, blood pressure, and appetite regulation.

Across my clinical experience, including insights I share publicly, sustained improvements in posture and gait mechanics correlate with higher physical activity adherence and more durable weight loss—factors that magnify the benefits of SGLT2 inhibitors and GLP-1 RAs. Cases presented on my platforms emphasize that stabilizing the axial skeleton can enable graduated aerobic conditioning, key to blood pressure control and improved endothelial function (Jimenez, n.d.-a; Jimenez, n.d.-b).

Navigating Side Effects and Clinical Considerations

While these medications are transformative, they require proactive management of side effects.

• Common Gastrointestinal Side Effects (GLP-1 RAs): The most common side effects are nausea, vomiting, and diarrhea, related to slowed gastric emptying. My clinical pearl is to “start low and go slow,” titrating the dose gradually. Eating smaller, more frequent meals and avoiding high-fat foods can help.
• Genital Mycotic Infections (SGLT2 inhibitors): Counsel on genital hygiene and consider topical therapies first.
• Gallbladder Disease (GLP-1 RAs): Rapid weight loss can increase the risk of gallstones.
• Thyroid C-Cell Tumors (GLP-1 RAs): Though the risk in humans is low, a black box warning is in place. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Anesthesia Risk (GLP-1 RAs): Due to delayed gastric emptying, guidelines recommend stopping these medications 1-2 weeks before scheduled surgery.

Clinical Takeaways for Patients and Clinicians

• Think risk first: For ASCVD, heart failure, or CKD, start with therapies that reduce events and death—SGLT2 inhibitors and GLP-1 receptor agonists.
• Combine wisely: SGLT2 + GLP-1 RA provides complementary mechanisms and broader protection.
• Move beyond glucose-only: Manage blood pressure, lipids, weight, sleep, and smoking; integrate rehabilitation to sustain physical activity.
• Integrative synergy: Chiropractic care, when coordinated with medical therapy and functional medicine, optimizes autonomic balance, mobility, and adherence—amplifying cardiometabolic benefits.
• Team care saves lives: Coordinated oversight by internal medicine, chiropractic, and functional medicine improves safety, precision, and the patient experience.

In my practice, integrating these powerful medical advancements with the foundational principles of chiropractic, functional medicine, and rehabilitation allows us to offer truly comprehensive care. By addressing the body as an interconnected whole, we can guide our patients on a journey not just to manage disease, but to achieve genuine, lasting wellness.

References

• American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care.
• American Diabetes Association. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178.
• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chordà, J., Chuquiure-Valenzuela, E., … & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451-1461.
• Cannon, C. P., et al. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes (VERTIS-CV). New England Journal of Medicine.
• Food and Drug Administration. (2008). Guidance for Industry: Diabetes Mellitus—Evaluating CV Risk in New Antidiabetic Therapies.S. FDA.
• Gerstein, H. C., et al. (2019). Dulaglutide and cardiovascular outcomes (REWIND). The Lancet.
• Heerspink, H. J. L., et al. (2020). Dapagliflozin in patients with CKD (DAPA-CKD). New England Journal of Medicine.
• Heise, T., Meneghini, L. F., DeVries, J. H., & Hermanski, L. (2011). The rationale for a new fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy, 11(10), 1289-1300.
• Jimenez, A. (n.d.-a). Clinical observations and integrative care insights.
• Jimenez, A. (n.d.-b). Professional profile and case discussions.
• Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes (LEADER). New England Journal of Medicine.
• Marso, S. P., et al. (2016). Semaglutide and cardiovascular outcomes (SUSTAIN-6). New England Journal of Medicine.
• McMurray, J. J. V., et al. (2019). Dapagliflozin in HFrEF (DAPA-HF). New England Journal of Medicine.
• Neal, B., et al. (2017). Canagliflozin and cardiovascular events (CANVAS). New England Journal of Medicine.
• Packer, M., et al. (2020). Empagliflozin in HFrEF (EMPEROR-Reduced). New England Journal of Medicine.
• The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in patients with CKD (EMPA-KIDNEY). New England Journal of Medicine.
• Wiviott, S. D., et al. (2019). Dapagliflozin and cardiovascular outcomes (DECLARE–TIMI 58). New England Journal of Medicine.
• Zinman, B., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality (EMPA-REG OUTCOME). New England Journal of Medicine.

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular outcomes, diabetes and heart disease, CKD protection, heart failure hospitalization, empagliflozin, dapagliflozin, liraglutide, semaglutide, tirzepatide, integrative chiropractic, functional medicine, multidisciplinary clinic, El Paso Texas, Injury Medical Clinic PA, autonomic balance, neuroimmune modulation, evidence-based guidelines, ADA 2023, CVOTs, over-basalization, MACE, A1c, Postprandial Glucose, Weight Loss, Diabetes Management, Insulin Resistance, Dr. Alex Jimenez, Dr. Maria Cardenas, musculoskeletal health, systemic inflammation